These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34052578)

  • 1. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.
    Ge S; Lu J; Hou Y; Lv Y; Wang C; He H
    Virology; 2021 Aug; 560():110-115. PubMed ID: 34052578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repositioning of histamine H
    Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
    Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.
    Hou Y; Ge S; Li X; Wang C; He H; He L
    Chem Biol Interact; 2021 Apr; 338():109420. PubMed ID: 33609497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
    Lu J; Hou Y; Ge S; Wang X; Wang J; Hu T; Lv Y; He H; Wang C
    Life Sci; 2021 Feb; 266():118889. PubMed ID: 33310043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2.
    Zhang Y; Hu S; Wang J; Xue Z; Wang C; Wang N
    Virology; 2021 Feb; 554():83-88. PubMed ID: 33387788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
    Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
    Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach.
    Lv Y; Wang S; Liang P; Wang Y; Zhang X; Jia Q; Fu J; Han S; He L
    Anal Bioanal Chem; 2021 May; 413(11):2995-3004. PubMed ID: 33608752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2.
    Yu F; Liu X; Ou H; Li X; Liu R; Lv X; Xiao S; Hu M; Liang T; Chen T; Wei X; Zhang Z; Liu S; Liu H; Zhu Y; Liu G; Tu T; Li P; Zhang H; Pan T; Ma X
    mBio; 2024 Aug; 15(8):e0108824. PubMed ID: 38953634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
    Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
    J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.
    Ahmad I; Pawara R; Surana S; Patel H
    Top Curr Chem (Cham); 2021 Oct; 379(6):40. PubMed ID: 34623536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection.
    Tai LT; Yeh CY; Chang YJ; Liu JF; Hsu KC; Cheng JC; Lu CH
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2.
    Hu S; Wang J; Zhang Y; Bai H; Wang C; Wang N; He L
    J Med Virol; 2021 May; 93(5):3143-3151. PubMed ID: 33580518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and anti-SARS-CoV-2 activity of amino acid modified cephalotaxine derivatives.
    Si M; An M; Xia Z; Mo X; Lu J; He H; Wang C
    Chem Biol Drug Des; 2024 Jun; 103(6):e14566. PubMed ID: 38858134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosensor-based active ingredient recognition system for screening potential small molecular Severe acute respiratory syndrome coronavirus 2 entry blockers targeting the spike protein from Rugosa rose.
    Yu W; Yi SZ; Jiang CY; Guan JW; Xue R; Zhang XX; Zeng T; Tang H; Chen W; Han B
    Biomed Chromatogr; 2024 Oct; 38(10):e5987. PubMed ID: 39126351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.